EUVIMEDOdkrijte EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC-ND 4.0

Efficacy and safety of hydroxychloroquine for treatment of mild SARS‐CoV ‐2 infection and prevention of COVID ‐19 severity in pregnant and postpartum women: A randomized, double‐blind, placebo‐controlled trial

Raquel González iD, Anna Goncé iD, Mª Del Mar Gil iD, Edurne Mazarico, Elena Ferriols-Pérez, Paloma Toro, Elisa Llurba, Elisa Saéz, Miguel Ángel Rodríguez-Zambrano, Laura García-Otero, Marta López, Belén Santacruz and 11 more

Acta Obstetricia et Gynecologica Scandinavica · 2024

DOI: 10.1111/aogs.14745 ↗

At a glance

Randomisierte kontrollierte Studie in Acta Obstetricia et Gynecologica Scandinavica, 2024. Written by Raquel González and 22 co-authors. Institution: ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain. Major MEDLINE topics: COVID-19. Cited 3 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Ministerio de Ciencia e Innovación.

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Introduction

Pregnant women have an increased risk of severe COVID‐19. Evaluation of drugs with a safety reproductive toxicity profile is a priority. At the beginning of the pandemic, hydroxychloroquine (HCQ) was recommended for COVID‐19 treatment. Material and methods A randomized, double‐blind, placebo‐controlled clinical trial was conducted in eight teaching hospitals in Spain to evaluate the safety and efficacy of HCQ in reducing viral shedding and preventing COVID‐19 progression. Pregnant and postpartum women with a positive SARS‐CoV‐2 PCR (with or without mild COVID‐19 signs/symptoms) and a normal electrocardiogram were randomized to receive either HCQ orally (400 mg/day for 3 days and 200 mg/day for 11 days) or placebo. PCR and electrocardiogram were repeated at day 21 after treatment start. Enrollment was stopped before reaching the target sample due to low recruitment rate.

Trial registration

EudraCT #: 2020‐001587‐29, on April 2, 2020. Clinical trials.gov # NCT04410562, registered on June 1, 2020.

Results

A total of 116 women (75 pregnant and 41 post‐partum) were enrolled from May 2020 to June 2021. The proportion of women with a positive SARS‐CoV‐2 PCR at day 21 was lower in the HCQ group (21.8%, 12/55) than in the placebo group (31.6%, 18/57), although the difference was not statistically significant ( P = 0.499). No differences were observed in COVID‐19 progression, adverse events, median change in QTc, hospital admissions, preeclampsia or poor pregnancy and perinatal outcomes between groups.

Conclusions

HCQ was found to be safe in pregnant and postpartum women with asymptomatic or mild SARS‐CoV‐2 infection. Although the prevalence of infection was decreased in the HCQ group, the statistical power was insufficient to confirm the potential beneficial effect of HCQ for COVID‐19 treatment.

Subjects

MeSH terms (MEDLINE)

COVID-19FemaleHumansPregnancySARS-CoV-2HydroxychloroquineCOVID-19 Drug TreatmentPostpartum PeriodDouble-Blind MethodTreatment Outcome

Author keywords

COVID-19SARS-CoV-2hydroxychloroquinepregnancyrandomized controlled trialwomen

Substances

Hydroxychloroquine

Authors and institutions

  • ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
  • Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP).
  • Manhiça Health Research Center (CISM), Manhiça, Mozambique.
  • BCNATAL | Barcelona Center for Maternal Fetal and Neonatal Medicine, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
  • Obstetrics and Gynecology Department, Hospital Universitario de Torrejón, Madrid, Spain.
  • School of Medicine, Universidad Francisco de Vitoria, Madrid, Spain.

ORCID profiles: Raquel González, Anna Goncé, Mª Del Mar Gil, Antoni Payà, Mónica Cruz-Lemini, Clara Pons-Duran, Azucena Bardají

Funding

  • Ministerio de Ciencia e Innovación

Cite

APA

González, R., Goncé, A., Gil, M. D. M., Mazarico, E., Ferriols-Pérez, E., Toro, P., Llurba, E., Saéz, E., Rodríguez-Zambrano, M. Á., García-Otero, L., López, M., Santacruz, B., Román, M. Á., Payà, A., Alonso, S., Cruz-Lemini, M., Pons-Duran, C., Herrera, L. B., Chen, H., …, & COVID-Preg research group (2024). Efficacy and safety of hydroxychloroquine for treatment of mild SARS‐CoV ‐2 infection and prevention of COVID ‐19 severity in pregnant and postpartum women: A randomized, double‐blind, placebo‐controlled trial. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.14745

Vancouver

González R, Goncé A, Gil MDM, Mazarico E, Ferriols-Pérez E, Toro P, et al. Efficacy and safety of hydroxychloroquine for treatment of mild SARS‐CoV ‐2 infection and prevention of COVID ‐19 severity in pregnant and postpartum women: A randomized, double‐blind, placebo‐controlled trial. Acta Obstetricia et Gynecologica Scandinavica. 2024. doi:10.1111/aogs.14745

BibTeX
@article{Gonzlez2024,
  author = {González, Raquel and Goncé, Anna and Gil, Mª Del Mar and Mazarico, Edurne and Ferriols-Pérez, Elena and Toro, Paloma and Llurba, Elisa and Saéz, Elisa and Rodríguez-Zambrano, Miguel Ángel and García-Otero, Laura and López, Marta and Santacruz, Belén and Román, Mª Ángeles and Payà, Antoni and Alonso, Sofia and Cruz-Lemini, Mónica and Pons-Duran, Clara and Herrera, Luis Bernardo and Chen, Haily and Bardají, Azucena and Quintó, Llorenç and Menendez, Clara and COVID-Preg research group, COVID-Preg research group},
  title = {Efficacy and safety of hydroxychloroquine for treatment of mild SARS‐CoV ‐2 infection and prevention of COVID ‐19 severity in pregnant and postpartum women: A randomized, double‐blind, placebo‐controlled trial},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2024},
  doi = {10.1111/aogs.14745}
}
Start for free →